[{"AccountsReceivableNetCurrent_0_Q1_USD":5189000000.0,"AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_0_Q1_USD":86000000.0,"AccountsPayableTradeCurrent_0_Q1_USD":1710000000.0,"PaymentsForProceedsFromOtherInvestingActivities_1_Q1_USD":-6000000.0,"DeferredTaxAssetsNetNoncurrent_0_Q1_USD":440000000.0,"OtherLiabilitiesCurrent_0_Q1_USD":1061000000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1_Q1_USD":-560000000.0,"SeniorNotes_0_Q1_USD":25687000000.0,"ProceedsFromSaleAndMaturityOfMarketableSecurities_1_Q1_USD":6000000.0,"LineOfCreditFacilityMaximumBorrowingCapacity_0_Q1_USD":2300000000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q1_USD":1804000000.0,"OtherAssetsCurrent_0_Q1_USD":538000000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q1_USD":540000000.0,"IncomeLossFromEquityMethodInvestments_1_Q1_USD":-1000000.0,"TreasuryStockValue_0_Q1_USD":4128000000.0,"TreasuryStockShares_0_Q1_shares":106000000.0,"InventoryFinishedGoodsNetOfReserves_0_Q1_USD":2193000000.0,"EarningsPerShareDiluted_1_Q1_USD":0.06,"SellingAndMarketingExpense_1_Q1_USD":613000000.0,"RepaymentsOfLongTermDebt_1_Q1_USD":700000000.0,"NetIncomeLossAvailableToCommonStockholdersBasic_1_Q1_USD":69000000.0,"LongTermDebtCurrent_0_Q1_USD":1116000000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1_Q1_USD":-33000000.0,"OtherComprehensiveIncomeLossNetOfTax_1_Q1_USD":-530000000.0,"ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_1_Q1_USD":-34000000.0,"ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1_Q1_USD":-505000000.0,"LongTermNotesAndLoans_0_Q1_USD":24473000000.0,"OtherLiabilitiesNoncurrent_0_Q1_USD":2624000000.0,"ProceedsFromPaymentsForOtherFinancingActivities_1_Q1_USD":0.0,"ValuationAllowancesAndReservesBalance_0_Q1_USD":5745000000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q1_USD":4357000000.0,"RestructuringReserve_0_Q1_USD":179000000.0,"RestructuringCharges_1_Q1_USD":39000000.0,"ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1_Q1_USD":221000000.0,"OtherOperatingActivitiesCashFlowStatement_1_Q1_USD":2000000.0,"OtherInventoryInTransit_0_Q1_USD":141000000.0,"OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax_1_Q1_USD":-30000000.0,"OperatingLeaseRightOfUseAsset_0_Q1_USD":489000000.0,"OperatingLeaseLiabilityNoncurrent_0_Q1_USD":411000000.0,"LossContingencyAccrualAtCarryingValue_0_Q1_USD":1539000000.0,"InventoryWorkInProcessNetOfReserves_0_Q1_USD":650000000.0,"InventoryRawMaterialsNetOfReserves_0_Q1_USD":1306000000.0,"ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_1_Q1_USD":724000000.0,"GoodwillForeignCurrencyTranslationGainLoss_1_Q1_USD":357000000.0,"FairValueNetAssetLiability_0_Q1_USD":1424000000.0,"EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1_Q1_USD":-28000000.0,"DeferredFinanceCostsNoncurrentNet_0_Q1_USD":98000000.0,"DebtInstrumentFairValue_0_Q1_USD":23543000000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1_Q1_USD":-171000000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q1_USD":30000000.0,"IncreaseDecreaseInOperatingCapital_1_Q1_USD":666000000.0,"ImpairmentOfLongLivedAssetsHeldForUse_1_Q1_USD":75000000.0,"DebtCurrent_0_Q1_USD":1630000000.0,"ImpairmentOfIntangibleAssetsExcludingGoodwill_1_Q1_USD":649000000.0,"ComprehensiveIncomeNetOfTax_1_Q1_USD":-471000000.0,"ValuationAllowancesAndReservesDeductions_1_Q1_USD":4410000000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q1_shares":1093000000.0,"OtherAssetsNoncurrent_0_Q1_USD":550000000.0,"ProfitLoss_1_Q1_USD":25000000.0,"PaymentsToAcquirePropertyPlantAndEquipment_1_Q1_USD":128000000.0,"OtherOperatingIncomeExpenseNet_1_Q1_USD":13000000.0,"NetIncomeLoss_1_Q1_USD":69000000.0,"NetCashProvidedByUsedInOperatingActivities_1_Q1_USD":305000000.0,"NetCashProvidedByUsedInInvestingActivities_1_Q1_USD":252000000.0,"NetCashProvidedByUsedInFinancingActivities_1_Q1_USD":-700000000.0,"LiabilitiesNoncurrent_0_Q1_USD":28420000000.0,"LiabilitiesCurrent_0_Q1_USD":12322000000.0,"LiabilitiesAndStockholdersEquity_0_Q1_USD":55330000000.0,"Liabilities_0_Q1_USD":40742000000.0,"PropertyPlantAndEquipmentNet_0_Q1_USD":6221000000.0,"InventoryNet_0_Q1_USD":4290000000.0,"GrossProfit_1_Q1_USD":2063000000.0,"GeneralAndAdministrativeExpense_1_Q1_USD":304000000.0,"EarningsPerShareBasicAndDiluted_1_Q1_USD":0.06,"DeferredTaxLiabilitiesNoncurrent_0_Q1_USD":912000000.0,"CommonStockValue_0_Q1_USD":56000000.0,"CommonStockSharesIssued_0_Q1_shares":1201000000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q1_USD":1804000000.0,"AssetsCurrent_0_Q1_USD":12884000000.0,"Assets_0_Q1_USD":55330000000.0,"AdditionalPaidInCapital_0_Q1_USD":27342000000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q1_USD":-2852000000.0,"IncomeTaxExpenseBenefit_1_Q1_USD":-59000000.0,"RetainedEarningsAccumulatedDeficit_0_Q1_USD":-6887000000.0,"StockholdersEquity_0_Q1_USD":13531000000.0,"AdjustmentForAmortization_1_Q1_USD":258000000.0,"NonoperatingIncomeExpense_1_Q1_USD":-224000000.0,"NetIncomeLossAttributableToNoncontrollingInterest_1_Q1_USD":-44000000.0,"MinorityInterest_0_Q1_USD":1057000000.0,"LitigationSettlementExpense_1_Q1_USD":25000000.0,"Goodwill_0_Q1_USD":24490000000.0,"FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0_Q1_USD":423000000.0,"EarningsPerShareBasic_1_Q1_USD":0.06,"CostOfGoodsAndServicesSold_1_Q1_USD":2294000000.0,"BusinessCombinationContingentConsiderationLiability_0_Q1_USD":435000000.0,"BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_1_Q1_USD":6000000.0,"StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0_Q1_USD":14588000000.0,"PrepaidExpenseCurrent_0_Q1_USD":977000000.0,"FiniteLivedIntangibleAssetsNet_0_Q1_USD":10256000000.0,"FiniteLivedIntangibleAssetsGross_0_Q1_USD":21361000000.0,"DerivativeLossOnDerivative_1_Q1_USD":493000000.0,"AmortizationOfIntangibleAssets_1_Q1_USD":258000000.0,"AllowanceForDoubtfulAccountsReceivableCurrent_0_Q1_USD":127000000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q1_shares":1096000000.0,"ShareBasedCompensation_1_Q1_USD":30000000.0,"OperatingIncomeLoss_1_Q1_USD":191000000.0,"FiniteLivedIntangibleAssetsAccumulatedAmortization_0_Q1_USD":11104000000.0,"DepreciationAndAmortization_1_Q1_USD":399000000.0,"CommonStockSharesAuthorized_0_Q1_shares":2495000000.0,"CommonStockParOrStatedValuePerShare_0_Q1_CHF":0.1,"CommitmentsAndContingencies_0_Q1_USD":null,"StockIssuedDuringPeriodValueNewIssues_1_Q1_USD":null,"EntityCommonStockSharesOutstanding_0_Q1_shares":1095524777.0,"Ticker":"TEVA","CIK":"818686","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","OfficialName":"Teva Pharmaceutical Industries Limited American Depositary Shares","form":"10-Q","period":"20200331","fy":"2020.0","fp":"Q1","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"11303387401.0","Country":"Israel","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NYSE","SP500":"nan","filed":"20200507"}]